FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884310040> ?p ?o ?g. }

• W2884310040 endingPage "20170172" @default.
• W2884310040 startingPage "20170172" @default.
• W2884310040 abstract "Objective: Two radiosensitizing chemotherapeutic drugs, capecitabine (CAP) and temozolomide (TEM), are administered concurrently to enhance the therapeutic efficacy of peptide receptor radionuclide therapy (PRRT). This study aims to assess the biodistribution and normal-organ and tumor radiation dosimetry for Lu-177 DOTATATE administered concurrently with CAP/TEM. Methods: 20 patients with non-resectable histologically confirmed gastroenteropancreatic neuroendocrine tumors with normal kidney function, a normal haematological profile and somatostatin receptor expression of the tumor lesions, as scintigraphically assessed by a Ga-68 DOTANOC scan, were included in two groups—case group (n = 10) and control group (n = 10). Patients included in case group were those who were advised concomitant CAPTEM therapy by the treating medical oncologist. Patients were administered CAP orally at a dose of 600mg m−2 bovine serum albumin twice a day for 14 days starting 9 days prior to PRRT and oral TEM as a single dose at a dose of 75 mg m−2 was given concurrently for the last 5 days commencing on the day of PRRT (days 9–14). In the control group, patients were treated with Lu-177 DOTATATE only. For PRRT, 6.4 GBq–7.6 GBq (173–207 mCi) of Lu-177 DOTATATE was administered as infusion into each patient over 10–15 min in a solution with positively charged amino acids for renal protection. Dosimetric calculations were done using the HERMES software. Results: Physiological uptake of Lu-177 DOTATATE was seen in all patients in liver, spleen kidneys, and bone marrow. Radiation absorbed doses (mean ± standard deviation) were obtained as 0.29 ± 0.12 mGy/MBq for kidneys, 0.30 ± 0.18 mGy/MBq for liver, 0.63 ± 0.37 mGy/MBq for spleen, 0.019 ± 0.001 mGy/MBq for bone marrow and 3.85 ± 1.74 mGy/MBq for tumours in the case group and they were 0.31± 0.26, 0.24 ± 0.14, 0.64 ± 0.42, 0.017 ± 0.016, 5.6 ± 11.27 mGy/MBq in kidneys, liver, spleen, bone marrow and neuroendocrine tumour, respectively, in the control group. Mann–Whitney U test between the variables of two groups showed an insignificant difference (p > 0.05). Conclusions: The authors demonstrated no significant difference between the tumor and organ doses with Lu-177 DOTATATE in the patients treated with and without concomitant chemotherapy. Advances in knowledge: To our knowledge, this is the first dedicated study exhibiting dosimetric analysis in patients undergoing PRRT in combination with chemotherapy." @default.
• W2884310040 created "2018-08-03" @default.
• W2884310040 creator A5005452063 @default.
• W2884310040 creator A5006334570 @default.
• W2884310040 creator A5017772500 @default.
• W2884310040 creator A5018356703 @default.
• W2884310040 creator A5021753682 @default.
• W2884310040 creator A5022689085 @default.
• W2884310040 creator A5028410057 @default.
• W2884310040 creator A5043346334 @default.
• W2884310040 creator A5067496394 @default.
• W2884310040 date "2018-11-01" @default.
• W2884310040 modified "2023-09-30" @default.
• W2884310040 title "Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM)" @default.
• W2884310040 cites W1508011599 @default.
• W2884310040 cites W1933764379 @default.
• W2884310040 cites W1966675362 @default.
• W2884310040 cites W1983680048 @default.
• W2884310040 cites W1985061998 @default.
• W2884310040 cites W2012856564 @default.
• W2884310040 cites W2017183061 @default.
• W2884310040 cites W2017884723 @default.
• W2884310040 cites W2045639544 @default.
• W2884310040 cites W2047019936 @default.
• W2884310040 cites W2047826871 @default.
• W2884310040 cites W2061335345 @default.
• W2884310040 cites W2076895614 @default.
• W2884310040 cites W2079241416 @default.
• W2884310040 cites W2088344186 @default.
• W2884310040 cites W2090232354 @default.
• W2884310040 cites W2097512974 @default.
• W2884310040 cites W2099478219 @default.
• W2884310040 cites W2125398839 @default.
• W2884310040 cites W2128544796 @default.
• W2884310040 cites W2130959358 @default.
• W2884310040 cites W2175610922 @default.
• W2884310040 cites W2215412034 @default.
• W2884310040 cites W2226900762 @default.
• W2884310040 cites W2254399833 @default.
• W2884310040 cites W2263248967 @default.
• W2884310040 cites W2316354129 @default.
• W2884310040 cites W2340889909 @default.
• W2884310040 cites W2346293763 @default.
• W2884310040 cites W2442741688 @default.
• W2884310040 cites W2465263678 @default.
• W2884310040 cites W2478491286 @default.
• W2884310040 cites W132414604 @default.
• W2884310040 doi "https://doi.org/10.1259/bjr.20170172" @default.
• W2884310040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6475937" @default.
• W2884310040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30028180" @default.
• W2884310040 hasPublicationYear "2018" @default.
• W2884310040 type Work @default.
• W2884310040 sameAs 2884310040 @default.
• W2884310040 citedByCount "21" @default.
• W2884310040 countsByYear W28843100402019 @default.
• W2884310040 countsByYear W28843100402020 @default.
• W2884310040 countsByYear W28843100402021 @default.
• W2884310040 countsByYear W28843100402022 @default.
• W2884310040 countsByYear W28843100402023 @default.
• W2884310040 crossrefType "journal-article" @default.
• W2884310040 hasAuthorship W2884310040A5005452063 @default.
• W2884310040 hasAuthorship W2884310040A5006334570 @default.
• W2884310040 hasAuthorship W2884310040A5017772500 @default.
• W2884310040 hasAuthorship W2884310040A5018356703 @default.
• W2884310040 hasAuthorship W2884310040A5021753682 @default.
• W2884310040 hasAuthorship W2884310040A5022689085 @default.
• W2884310040 hasAuthorship W2884310040A5028410057 @default.
• W2884310040 hasAuthorship W2884310040A5043346334 @default.
• W2884310040 hasAuthorship W2884310040A5067496394 @default.
• W2884310040 hasBestOaLocation W28843100402 @default.
• W2884310040 hasConcept C121608353 @default.
• W2884310040 hasConcept C126322002 @default.
• W2884310040 hasConcept C126894567 @default.
• W2884310040 hasConcept C170493617 @default.
• W2884310040 hasConcept C2776297358 @default.
• W2884310040 hasConcept C2777389519 @default.
• W2884310040 hasConcept C2777909004 @default.
• W2884310040 hasConcept C2779066768 @default.
• W2884310040 hasConcept C2779384505 @default.
• W2884310040 hasConcept C2781025020 @default.
• W2884310040 hasConcept C2989005 @default.
• W2884310040 hasConcept C2993559085 @default.
• W2884310040 hasConcept C3017732841 @default.
• W2884310040 hasConcept C509974204 @default.
• W2884310040 hasConcept C526805850 @default.
• W2884310040 hasConcept C71924100 @default.
• W2884310040 hasConcept C75088862 @default.
• W2884310040 hasConcept C80115893 @default.
• W2884310040 hasConcept C90924648 @default.
• W2884310040 hasConceptScore W2884310040C121608353 @default.
• W2884310040 hasConceptScore W2884310040C126322002 @default.
• W2884310040 hasConceptScore W2884310040C126894567 @default.
• W2884310040 hasConceptScore W2884310040C170493617 @default.
• W2884310040 hasConceptScore W2884310040C2776297358 @default.
• W2884310040 hasConceptScore W2884310040C2777389519 @default.
• W2884310040 hasConceptScore W2884310040C2777909004 @default.
• W2884310040 hasConceptScore W2884310040C2779066768 @default.
• W2884310040 hasConceptScore W2884310040C2779384505 @default.

• next